Immune checkpoint inhibitors (ICIs), as a novel class of anticancer drugs, have therefore hold a great therapeutic potential on the management of advanced NSCLC patients, especially those with a high level of PD-L1 expression (Gridelli and Casaluce, 2018; Hanna et al., 2020). This evidence concerns the gene CD274 and non-small cell lung carcinoma.